The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

New Delhi: A personalised mRNA vaccine reduced the chances of high-risk melanoma returning or spreading in a Phase 3 trial, US-based pharma companies Moderna and Merck said Wednesday. The vaccine was ...

Investors Should Know: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma ...

Moderna’s dramatic ascent this year has been fueled by optimism that its personalized cancer vaccine could reshape oncology and redefine the company beyond its pandemic-era success. That promise may ...

Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA’s upside hinges on Intismeran’s ability to scale across multiple tumor types ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

The Independent and Yahoo will earn a commission from purchases made via links in this article. Pricing and availability are subject to change. A personalised vaccine given in combination with a drug ...

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...